A pioneering new report offers an overview of pharma RWS/RCT industry developments in 2020-2021, Asia’s RWS market size, trends there and in China - where it predicts 40 percent yearly growth - and showcases Asian RWS industry leaders. It discusses use of virtual Twin Studies, GWAS, Pharmacovigilance and AI, and explores RWS and AI used in diagnostics, biomarkers, image analysis, disease prevention, and Big Data. It then cites the challenges and opportunities faced by AI-driven WRS and lists governmental regulations on RWS and Big Data in Asia.